Abstract: Methods of improving (i.e., changing) the skin of a patient or consumer who does not have sensitive, dry, very oily, pigmented and/or wrinkle-prone skin to slightly oily, resistant non-pigmented and tight skin.

Abstract: Provided are hair care compositions comprising: (a) a cellulose ether having (i) a methoxy substitution of from 21 to 42 weight % based upon the weight of the cellulose ether, (ii) a hydroxypropyl substitution of from 0 to 32 weight % based upon the weight of the cellulose ether, (iii) a viscosity of from 15 cP to less than 4,000 cP in a two percent aqueous solution at 20° C., and (iv) either a gelation temperature of greater than 45° C. or a hydration temperature of 25° or higher; and (b) at least one hair fixative polymer, conditioning agent, or humectant.

Abstract: A solid lip cosmetic provides excellent effects of being prevented from secondary adhesion and also has excellent usability, long-lasting glossiness and stability. A solid lip cosmetic is characterized by comprising (a) 25 to 50% by mass of hydrogenated polyisobutene; (b) 20 to 70% by mass of at least one methylphenylsilicone component that can be separated from the component (a) when the component (b) is mixed with the component (a) at 25° C.; (c) 1 to 20% by mass of neopentyl glycol dicaprate that serves as a compatibility modifier that can adjust the compatibility of the component (a) with the component (b); and (d) 3 to 12% by mass of a wax.

Abstract: Methods for use in selectively conditioning and remineralizing teeth. An exemplary method comprises the steps of applying a conditioning composition to one or more of a person's teeth, and separately applying a remineralizing composition to the person's teeth. The conditioning composition includes a conditioning agent, and the remineralizing composition includes a remineralizing agent comprising calcium ions and/or fluoride ions. The conditioning composition may be applied prior to or after application of the remineralizing composition. In one embodiment, both the conditioning composition and the remineralizing composition include different remineralizing ions (e.g., one including calcium, one including fluoride).

Abstract: Technologies are described for a method and constituents for mitigating dag on hair. The method comprises applying a hydrophobic silicon containing constituent and a reactive constituent onto the hair. The reactive constituent enables a reaction with the hair that binds the hydrophobic silicon constituent to the hair and the hydrophobic silicon constituent imparts its hydrophobicity to the hair to mitigate dag on the hair.

Abstract: A composition with exogenous mitochondria as active ingredients, and a use thereof and a cell repairing method therefor. The composition includes exogenous mitochondria and at least one pharmaceutically or cosmetically acceptable carrier. The composition may further include an adjuvant, and the adjuvant is selected from a group consisting of serum, plasma, complement and at least the above two ingredients. The exogenous mitochondria are obtained from cells by a centrifugal purification method.

Abstract: A drug dosage form is provided in the form of a solid tablet which is greater than 50% by weight the local anesthetic agent. The local anesthetic agent may be selected from the group consisting of an aminoamide, an aminoester, and a combination thereof. The drug tablet may be in the form of a mini-tablet which is greater than 70 wt % drug, with the balance being excipient. For example, the anesthetic agent may include lidocaine, in a salt or base form, combined with binder and lubricant excipients. Implantable drug delivery devices including the tablets are also provided, e.g., one or more of the drug tablets may be contained in a biocompatible housing. The drug tablets may be substantially cylindrical with flat end faces, and the device may have from 10 to 100 drug tablets aligned in the housing with the flat end faces of adjacent tablets abutting one another.

Abstract: The present invention provides injectable formulations of (2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol and hydrates thereof and methods for treating disorders in which DOT 1-mediated protein methylation plays a part, such as cancer and neurological disorders.

Abstract: A soft chewable pharmaceutical product for delivery of a pharmaceutically acceptable active ingredient to an animal comprising pamoic acid or a pharmaceutically acceptable salt and a process for the manufacture of such soft chewable pharmaceutical product.

Abstract: Disclosed herein are novel compositions and methods for treating or preventing upper GI tract disorders and protecting stratified squamous epithelium against injury by a noxious substance. The methods generally include administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition comprising at least one bile acid sequestrant, alone or in combination with at least one proton pump inhibitor, and optionally one or more agent chosen from antacids, histamine H2-receptor antagonists, ?-aminobutyricacid-b (GABA-B) agonists, prodrugs of GABA-B agonists, and protease inhibitors.

Abstract: A composition-of-matter is provided. The present composition includes dietary supplements capable of reducing or reversing the negative effects of alcohol on motor and cognition, dietary supplements having anti-gastroparesis, antiemetic, analgesic and anti-inflammatory activities and/or dietary supplements capable of increasing alcohol catabolism and decreasing the level of toxic products of alcohol catabolism.

Abstract: Provided herein are topical formulations. The topical formulation may comprise: (i) pregabalin, (ii) water, (iii) DMSO, (iv) a keto acid, and (v) and/or a fatty alcohol. The topical formulation may also comprise (i) pregabalin, (ii) DMSO, (iii) a keto acid and (iv) a fatty acid ester. It has been discovered that the combinations of DMSO with a keto acid such as levulinic acid and/or and a fatty acid ester such as lauryl lactate, or combinations of DMSO with a keto acid such as levulinic acid and/or with a fatty alcohol such as oleyl alcohol are excellent penetration enhancers and, as such, can be incorporated in a skin-applied formulation to facilitate administration of pregabalin.

Abstract: Antimicrobial peptides represent a relatively new discovery in the immune system pathway. Recent designs of synthetically engineered antimicrobial peptides have demonstrated increased potency and efficacy/tolerability, enhanced specificity, and reduced toxicity in comparison. One such peptide, XYLENTRA, has shown/demonstrated significant promise from significant in vitro studies against a large number of pathogens. Additionally, extensive animal studies have shown that the XYLENTRA is an antimicrobial peptide against a large number of pathogens. The XYLENTRA is also solute resistant. The test compound Xylentra® has shown/demonstrated significant antibacterial activity on test organisms Staphylococcus aureus MTCC 96 and Pseudomonas aeruginosa. MTCC741.

Abstract: In accordance with the present invention, disclosed herein is a kit comprising a first mixture comprising a pharmaceutically acceptable polar liquid and a fully or nearly fully dissolved biodegradable polymer; a second mixture comprising a pharmaceutically acceptable non-polar liquid; and a mixing device configured to mix the first mixture and second mixture, thereby forming a droplet comprising the biodegradable polymer. Also disclosed herein are methods of producing a microparticle in vivo in a subject.

Abstract: Pharmaceutical compositions comprising stabilized self-assembling amphiphilic molecular structure (SAMS) having average diameters of 120 nm or less with a low zeta potential of less than 30 mV to be used for Total Parenteral Nutrition (TPN) or Total Parenteral Alimentation (TPA), increase blood pressure, renal dialysis, transport and release hydrophobic gases, exchange transfusion to replace blood, extracorporeal membrane oxygenation (ECMO), open constricted or blocked blood vessels, treat septic shock and irreversible shock due to sepsis and/or severe blood loss irreversible septic shock, treat dilutional coagulopathy of severe blood loss and bleeding with loss of clotting factors, and replace lost volume in childhood diseases that cause hypovolemia or severe hypovolemia, treat traumatic brain injury, burns, diagnosis of diseases and methods of making and using said compositions.

Abstract: The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysfunction.

Abstract: The present invention relates to a composition comprising a neurokinin-1 receptor antagonist and at least one excipient selected from an oil, a fatty acid or a polyol, as well as to an administration form for administering a formulation, wherein said administration form is selected from: inhalant, nebulization, vapor, smoke or aerosol and comprises said composition. In addition, the invention relates to said composition for use as medicament, said administration form for use as medicament, preferably said composition for use as medicament in the treatment of at least one disease of the respiratory tract, or said administration form for use as medicament in the treatment of at least one disease of the respiratory tract. Moreover, the invention also provides methods for producing said composition and said administration form, as well as a kit of parts comprising said composition and an administration device.

Abstract: The present invention discloses methods for manufacturing drug delivery composition comprising at least one pharmaceutically active compound, at least one anti-caking agent and at least one oil. The anti-caking agent and the oil form the matrix when mixed, which then embeds the pharmaceutically active compound.

Abstract: Pharmaceutical compositions having enhanced active component permeation properties are described.

Abstract: The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.

Abstract: Compositions for transdermal delivery of an active agent and methods for using such compositions are described herein.

Abstract: A double disk dermal device for administration of one or more active agents to the skin or mucosa of a host, in particular a patch is described including: a) active reservoir film layer; b) a backing overlay adjacent to the active reservoir film layer extending beyond the perimeter of the reservoir layer in all directions; c) second overlay backing layer with a coating of pressure sensitive adhesive which is adjacent to the first backing overlay extending beyond the perimeter of the first backing overlay in all directions; and d) a removable release liner. A method of making the device is also provided.

Abstract: The present invention relates to a transdermal composition for dementia treatment containing donepezil as an active ingredient. The transdermal composition according to the present invention contains highly concentrated donepezil in a hydrophobic matrix, can continuously release the drug for a long time by having excellent long-term adhesion to the skin, and further exhibits consistently effective therapeutic effects over a long period of time by having a significantly improved skin penetration rate in comparison with conventional donepezil patches.

Abstract: The present disclosure provides a pharmaceutical preparation of a compound of formula (I) or a stereoisomer, pharmaceutically acceptable salt, or prodrug thereof. The present disclosure further provides a method for general anesthesia or sedation for mammals. Also provided are kits and manufactured products of the medicament and the pharmaceutical composition and a method for using the medicament and the pharmaceutical composition.

Abstract: The present invention relates to a polyphenol derivative of the stilbenoid family, namely trans-3,5,4?-trihydroxybibenzyl, also known as dihydro-resveratrol, as a remedial agent. In particular, the present invention presents the usage of dihydro-resveratrol as an anti-fibrotic agent in suppressing the activation of pancreatic stellate cells (PSCs). One embodiment of the present invention also relates to the management of pancreatic fibrosis, which is often accompanied with chronic pancreatitis and desmoplastic reaction of pancreatic cancer. Another embodiment of the present invention also has applications in preventing or alleviating or treating pancreatic cancer or pancreatogenic diabetes.

Abstract: There is provided an exemplary method of treating weaning piglets to induce weight gain, or to prevent a reduction in rate of weight gain, the method comprising exposing the weaning piglets to a rabbit maternal pheromone having an interomone effect. In an exemplary embodiment, the rabbit maternal pheromone is trans-2-methyl-2-butenal. The method may include the step of applying the rabbit maternal pheromone to a feeder for the weaning piglets. Moreover, the rabbit maternal pheromone may be applied to a feeder (or to the feed) for the weaning piglets at least once during a first week of weaning. Further, the method may include weighing the weaning piglets at intervals to determine a rate of weight gain, and measuring an amount of feed consumed by the weaning piglets to calculate the amount of weight gained per unit of feed consumed.

Abstract: Methods for reducing MSK1 levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 5% curcumin III. Methods for inhibiting MSK1 serine376 phosphorylation in a plurality of cells are also disclosed, which include providing to the cells a curcumin composition that is at least 5% curcumin III. In addition, methods for ameliorating inflammation in a subject are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. Still further, methods for ameliorating symptoms in a subject having glucocorticoid-resistant inflammatory disease are disclosed, which include providing to a subject a curcumin composition that is at least 5% curcumin III. In addition, compositions are disclosed that include a curcumin composition consisting of at least 5% curcumin III; glucocorticoids; and a pharmaceutically acceptable solvent, filler, or carrier.

Abstract: Methods for modulating miRNA148a levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 5% curcumin III, in order to increase miRNA148a levels. In addition, compositions for elevating miRNA148a levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 5% curcumin III and a pharmaceutically-acceptable solvent, filler, or carrier.

Abstract: The invention is directed to methods and compositions of stabilizing phenylephrine formations. The composition has good time-dependent stability at low temperature and has no change in its outward appearance even after having been stored at least 6 months.

Abstract: A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol.

Abstract: Disclosed herein are new oral pharmaceutical compositions of MGBG and related polyamine analogs, polyamine biosynthesis inhibitors, polyamine inhibitors of AMD-I and regulators of osteopontin, and their application for the treatment of disease.

Abstract: An isotonic irrigation solution for wounds, surgical incisions and as a lavage, the irrigation solution comprising saline, antimicrobial, chelator, surfactant and collagenous biological enhancer.

Abstract: The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

Abstract: The present invention relates to kartogenin-conjugated chitosan particles with an improved sustained release property and biocompatibility. Effects of increases in biocompatibility, chondrogenic differentiation efficiency and retention time in the joints were confirmed by using kartogenin-chitosan microparticles or kartogenin-chitosan nanoparticles of the present invention, and thus targeted treatment, in the prevention or treatment of bone diseases, is enabled through a more fundamental approach.

Abstract: Compositions and methods for providing a person with an exogenous and therapeutically effective supply of ketones are disclosed. The compositions may consist essentially of (a) purified butyrate (or esters or propionate salts thereof) and (b) purified beta-hydroxybutyrate (or esters or propionate salts thereof). The compositions may further include other pharmacologically active agents, such as acetyl-L carnitine, R-alpha lipoic acid, green tea extract, vitamins, and various combinations of such agents. The methods include providing a person with an exogenous supply of ketones, by orally administering a pharmacologic composition, which is effective to deliver 2000-5000 mg of a short chain fatty acid (e.g., butyrate) and 5000-10,000 mg of ketone (e.g., beta-hydroxybutyrate) on a daily basis.

Abstract: Formulations, methods of manufacturing, methods of stabilizing, kits, and uses as medicament are provided, for example for the treatment of pain. The formulations can comprise gabapentin optionally combined with at least one non-opioid pain drug in an aqueous carrier. The pharmaceutical formulation can have a pH of about 2.0 to about 10.0. The at least one non-opioid pain drug can be acetaminophen. The components can be included in any amount suitable for purposes of obtaining properties desirable for an injectable infusion, for example an intravenous infusion.

Abstract: A method for treating eczema including the steps of applying an isothiocyanate functional surfactant to an area affected by eczema, wherein the isothiocyanate functional surfactant comprises at least one isothiocyanate functional group associated with an aliphatic and/or aromatic carbon atom of the isothiocyanate functional surfactant.

Abstract: Provided are a compound represented by the following Formula (III), a tautomer or stereoisomer of the compound, or a pharmaceutically acceptable salt or solvate thereof used as a therapeutic agent for gout or hyperuricemia.

Abstract: Provided herein is combination cancer therapy effected by administering a polymer-conjugated hyaluronidase, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.

Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

Abstract: The present invention is directed to methods for reducing blood lactate concentration during exercise, physical activity or athletic performance.

Abstract: Composition for topical application, for use in increasing the trophism of nasal mucosa, comprising an ester of vitamin E with a carboxylic acid of formula R—COOH, in which R is an alkyl radical having 1 to 19 carbon atoms, or an alkenyl or alkynyl radical having 2 to 19 carbon atoms, and an oily vehicle; such composition can be used for the treatment of chronic atrophic rhinitis and for obtaining tissue repair of the nasal mucosa following nasal and sinus surgery.

Abstract: Disclosed are compositions comprising (a) a GPR40 agonist and (b) an SGLT2 inhibitor, and methods for treating of disorders that are affected by the modulation of the GPR40 receptor and SGLT2 transporter. Such GPR40 compounds are represented by Formula (I) as follows: wherein ring W, R1, R2, R3, R5, R6, A, and Z, are defined herein.

Abstract: The invention encompasses pet food composition that delivers a slow, sustained-release amount of lipoic acid or a salt thereof when fed orally to a companion animal. The invention also encompasses methods of manufacture and use of the compositions.

Abstract: The present invention is directed to the treatment of small fibre neuropathy comprising administering to a subject in need thereof, a therapeutically effective amount of 5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-prolinamide or a pharmaceutically acceptable salt, solvate or prodrug thereof.

Abstract: The invention relates to oral, topical or injectable compositions for combating liver fluke parasites in mammals, comprising at least one indole derivative active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections and infestations in a mammal comprising administering the compositions of the invention to the mammal in need thereof.

Abstract: A pharmaceutical or cosmetic composition comprising an Indigo Naturalis or Indigo-producing plant extract for treating atopic dermatitis and any form of eczema, and a method of treating atopic dermatitis comprising administering a therapeutically effective amount of an Indigo Naturalis or Indigo-producing plant extract to a subject in need thereof are described.

Abstract: The present invention provides extended release pharmaceutical formulations of valsartan with controlled impurity levels. Particularly, the present invention provides extended release valsartan formulation which is substantially free of valsartan R-isomer impurity.

Abstract: The present invention relates to compositions and methods for treating lipid disorders in a subject. In one embodiment, the compositions of the present invention can be used to inhibit protease proprotein convertase subtilisin-like kexin type 9 (PCSK9). In another embodiment, the compositions of the present invention can be used to disrupt the protein-protein interaction between PCSK9 and low-density lipoprotein receptor (LDLR).

Abstract: The present invention relates to Film Compositions of Ondansetron or its pharmaceutically acceptable salt thereof, which dosage forms are useful for the treatment of various medical conditions.